Today
-0.54%
5 Days
-8.36%
1 Month
-8.27%
6 Months
+22.14%
Year to Date
+20.59%
1 Year
+50.52%
• ResMed gross margins contracted due to product mix shifts and elevated logistical expenses. • Concerns over GLP-1 weight-loss drugs create long-term uncertainty for CPAP market growth. • Increased competition and higher operating expenses are pressuring short-term profitability and investor sentiment.
• CVS Health shares declined following an earnings report highlighting increased medical benefit ratios. • Management lowered full-year earnings guidance due to rising costs and retail pharmacy pressures. • Regulatory scrutiny regarding pharmacy benefit manager practices has introduced significant policy uncertainty.
• CVS Health launched new GLP-1 weight management services and virtual consultation programs. • Financial analysts raised price targets following the company's strategic expansion into GLP-1 markets. • CVS reported improved quarterly earnings and updated guidance amid ongoing operational restructuring efforts.
• Bank of America upgraded UnitedHealth Group to "buy" with a higher price target. • UnitedHealth's Q1 earnings exceeded expectations due to operational efficiency. • AI investments and increased dividend signal company confidence and shareholder returns.
• CVS Health shares rose on strong earnings and analyst upgrades. • Health Care Benefits segment, especially Aetna, showed improved performance. • Analysts raised price targets, indicating positive sentiment and confidence.
• Stryker reaffirms full-year guidance despite Q1 cyber incident impact. • Acquisition of Amplitude Vascular Systems expands peripheral portfolio. • Quarterly dividend increased 4.8% to $0.88 per share.


| Shareholders | Proportion |
|---|---|
| Vanguard Capital Management, LLC | 6.48% |
| Capital World Investors | 5.30% |
| BlackRock Institutional Trust Company, N.A. | 5.09% |
| Dodge & Cox | 4.90% |
| Shareholder Types | Proportion |
|---|---|
| Investment Advisor | 47.14% |
| Investment Advisor/Hedge Fund | 30.56% |
| Hedge Fund | 3.66% |
| Research Firm | 2.90% |
Related Instruments
Popular Instruments